Johnson & Johnson on Tuesday sued the Biden administration in a controversy over how it distributes rebates under the federal ...
Zacks.com on MSN2h
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have lost about 6.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...
Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Johnson & Johnson MedTech announced today that it entered into an exclusive commercial distribution agreement with Responsive Arthroscopy. The company agreed to a deal in the U.S. with Responsive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback